Vimarsana
Biggest News Aggregation in the World

Page 29 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Voluntary withdrawal Imfinzi US bladder indication - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Voluntary withdrawal Imfinzi US bladder indication

  in advanced bladder cancer in the US   AstraZeneca today announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or metastatic bladder cancer. This decision was made in consultation with the Food and Drug Administration (FDA).   In May 2017, Imfinzi was granted accelerated approval in the US based on promising tumour response rates and duration of response data from Study 1108, a Phase I/II trial that evaluated the safety and efficacy of Imfinzi in advanced solid tumour...

Astrazeneca PLC (NYSE:AZN) - Why AstraZeneca Is Voluntarily Withdrawing Imfinzi In US For Advanced Bladder Cancer Indication - Vimarsana News

Astrazeneca PLC (NYSE:AZN) - Why AstraZeneca Is Voluntarily Withdrawing Imfinzi In US For Advanced Bladder Cancer Indication

AstraZeneca plc (NASDAQ: AZN) announced Monday a setback related to its key immuno-oncology therapy Imfinzi. What Happened: The U.K. drugmaker said it is ...

Setback for AstraZeneca checkpoint inhibitor in US bladder cancer treatment - Vimarsana News

Setback for AstraZeneca checkpoint inhibitor in US bladder cancer treatment

Setback for AstraZeneca checkpoint inhibitor in US bladder cancer treatment AstraZeneca is voluntarily withdrawing the use of its cancer drug, Imfinzi, to treat advanced bladder cancer in the US after it did not meet post-approval requirements. This decision was made in consultation with the Food and Drug Administration (FDA). Imfinzi (durvalumab) is a human monoclonal antibody that is designed to bind to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumor's immune-evading tactics and releasing the inhibition of immune responses.  R...

AstraZeneca (AZN) Q4 2020 Earnings Call Transcript - Vimarsana News

AstraZeneca (AZN) Q4 2020 Earnings Call Transcript

Operator Good morning to those joining from the U.K. and the U.S. Good afternoon to those in Central Europe. Welcome, ladies and gentlemen, to AstraZeneca's full-year 2020 results conference call and webcast for investors and analysts. Before I hand it over to AstraZeneca, I'd like to read the safe harbor statement. The company intends to utilize the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca. Although we belie...

Source: fool.com
AZ's Imfinzi fails to improve overall survival in head and neck cancer again - Vimarsana News

AZ's Imfinzi fails to improve overall survival in head and neck cancer again

Immunotherapy has previously failed in this therapy area - News - PharmaTimes